Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease

NCT02035553 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT02035553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02035553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
October 27, 2016
Enrollment
181 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease psychosis